Rakesh K Jain Selected Research

cediranib (AZD2171)

4/2016	Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages.
10/2015	A phase I study of cediranib in combination with cilengitide in patients with recurrent glioblastoma.
1/2014	Low incidence of pseudoprogression by imaging in newly diagnosed glioblastoma patients treated with cediranib in combination with chemoradiation.
11/2013	Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation.
9/2013	Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma.
6/2013	Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers.
3/2013	Efficacy, safety, pharmacokinetics, and biomarkers of cediranib monotherapy in advanced hepatocellular carcinoma: a phase II study.
1/2012	Increased survival of glioblastoma patients who respond to antiangiogenic therapy with elevated blood perfusion.
10/2011	T(1)- and T(2)(*)-dominant extravasation correction in DSC-MRI: part II-predicting patient outcome after a single dose of cediranib in recurrent glioblastoma patients.
6/2011	Serial magnetic resonance spectroscopy reveals a direct metabolic effect of cediranib in glioblastoma.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Rakesh K Jain Research Topics

Disease

267	Neoplasms (Cancer) 11/2022 - 01/2002
46	Neoplasm Metastasis (Metastasis) 01/2022 - 04/2004
42	Glioblastoma (Glioblastoma Multiforme) 11/2021 - 03/2002
33	Breast Neoplasms (Breast Cancer) 11/2021 - 08/2002
27	Hypoxia (Hypoxemia) 01/2022 - 01/2005
24	Brain Neoplasms (Brain Tumor) 12/2021 - 12/2004
17	Hepatocellular Carcinoma (Hepatoma) 01/2022 - 06/2009
15	Carcinoma (Carcinomatosis) 12/2021 - 04/2002
12	Glioma (Gliomas) 10/2018 - 03/2002
11	Inflammation (Inflammations) 01/2021 - 04/2004
10	Colorectal Neoplasms (Colorectal Cancer) 11/2021 - 06/2004
10	Edema (Dropsy) 01/2021 - 01/2007
10	Lymphatic Metastasis 09/2015 - 06/2002
10	Rectal Neoplasms (Rectal Cancer) 01/2010 - 02/2004
9	Hypertension (High Blood Pressure) 01/2022 - 03/2007
7	Disease Progression 03/2021 - 03/2002
7	Fibrosis (Cirrhosis) 01/2021 - 04/2014
7	Neurilemmoma (Schwannoma) 01/2021 - 07/2009
7	Adenocarcinoma 11/2019 - 05/2004
6	Necrosis 04/2016 - 05/2008
5	Renal Cell Carcinoma (Grawitz Tumor) 01/2022 - 07/2005
5	Infections 01/2022 - 11/2011
5	Sarcoma (Soft Tissue Sarcoma) 11/2021 - 11/2007
5	Triple Negative Breast Neoplasms 08/2021 - 07/2011
5	Pancreatic Neoplasms (Pancreatic Cancer) 07/2019 - 01/2013
5	Obesity 01/2018 - 01/2009
4	COVID-19 01/2022 - 09/2020
4	Hearing Loss (Hearing Impairment) 01/2021 - 11/2015
4	Neurofibromatosis 2 (Neurofibromatosis Type II) 01/2019 - 07/2009
4	Acoustic Neuroma (Acoustic Neurinoma) 01/2018 - 07/2009
4	Lung Neoplasms (Lung Cancer) 07/2015 - 01/2006
4	Hyperplasia 04/2009 - 07/2004
3	Thrombosis (Thrombus) 01/2021 - 04/2002
3	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2019 - 02/2015
3	Ascites 01/2019 - 04/2009

Drug/Important Bio-Agent (IBA)

73	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2021 - 03/2002
49	Biomarkers (Surrogate Marker)IBA 01/2022 - 11/2005
47	Pharmaceutical PreparationsIBA 01/2022 - 08/2002
37	Bevacizumab (Avastin)FDA Link 06/2021 - 12/2002
21	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 11/2020 - 01/2006
18	CollagenIBA 01/2018 - 09/2002
18	cediranib (AZD2171)IBA 04/2016 - 01/2007
17	Oxygen (Dioxygen)IBA 01/2022 - 04/2002
14	Immune Checkpoint InhibitorsIBA 01/2022 - 05/2015
14	Angiogenesis InhibitorsIBA 01/2020 - 01/2005
14	Tyrosine Kinase InhibitorsIBA 01/2017 - 07/2005
11	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2022 - 04/2002
9	Hyaluronic Acid (Hyaluronan)IBA 01/2018 - 09/2002
8	AngiotensinsIBA 01/2022 - 01/2013
8	Losartan (Cozaar)FDA LinkGeneric 01/2022 - 02/2011
8	Sorafenib (BAY 43-9006)FDA Link 01/2021 - 07/2009
8	Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA 01/2020 - 02/2003
7	Biological ProductsIBA 10/2020 - 04/2011
7	Temozolomide (Temodar)FDA LinkGeneric 01/2020 - 06/2011
7	Fluorouracil (Carac)FDA LinkGeneric 11/2019 - 10/2006
7	Proteins (Proteins, Gene)FDA Link 01/2019 - 03/2002
7	Phosphotransferases (Kinase)IBA 04/2014 - 01/2006
6	Monoclonal AntibodiesIBA 01/2022 - 12/2002
6	Angiotensin Receptor AntagonistsIBA 01/2022 - 10/2016
6	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2022 - 11/2008
6	CytokinesIBA 01/2021 - 10/2009
6	Sunitinib (Sutent)FDA Link 09/2015 - 09/2007
6	Vascular Endothelial Growth Factor CIBA 04/2009 - 06/2002
5	RNA (Ribonucleic Acid)IBA 01/2022 - 09/2011
5	LigandsIBA 12/2021 - 05/2008
5	AntigensIBA 01/2020 - 09/2002
5	plerixafor FDA Link 01/2019 - 07/2010
4	Neuropilin-1IBA 01/2022 - 07/2009
4	cabozantinibIBA 08/2021 - 01/2017
4	Trastuzumab (Herceptin)FDA Link 01/2020 - 11/2012
4	Oxaliplatin (Eloxatin)FDA LinkGeneric 11/2019 - 06/2011
4	Angiopoietin-1IBA 01/2018 - 04/2002
4	EnzymesIBA 01/2016 - 03/2002
4	Vascular Endothelial Growth Factor Receptor-1 (fms-Like Tyrosine Kinase)IBA 01/2016 - 07/2009
4	Matrix Metalloproteinases (MMPs)IBA 04/2015 - 12/2004
4	Placenta Growth FactorIBA 11/2013 - 04/2006
4	Complementary DNA (cDNA)IBA 06/2011 - 07/2005
4	Chemokine CXCL12IBA 04/2011 - 10/2009
4	Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)IBA 01/2011 - 07/2005
4	Fibrillar CollagensIBA 06/2007 - 06/2003
3	Interleukin-6 (Interleukin 6)IBA 01/2022 - 01/2018
3	Transforming Growth Factors (Transforming Growth Factor)IBA 12/2021 - 04/2015
3	AntibodiesIBA 11/2021 - 01/2017
3	Glucose (Dextrose)FDA LinkGeneric 01/2020 - 04/2002
3	Leucovorin (Folinic Acid)FDA Link 11/2019 - 01/2019
3	Irinotecan (Camptosar)FDA LinkGeneric 07/2019 - 08/2007
3	Protons (Proton)IBA 07/2019 - 06/2011
3	Paclitaxel (Taxol)FDA LinkGeneric 01/2019 - 05/2008
3	Immunoconjugates (Immunoconjugate)IBA 01/2019 - 02/2016
3	CXCR4 Receptors (CXCR4 Receptor)IBA 01/2019 - 10/2009
3	Ado-Trastuzumab EmtansineIBA 01/2019 - 02/2016
3	Metformin (Glucophage)FDA LinkGeneric 01/2018 - 01/2015

Therapy/Procedure

145	Therapeutics 01/2022 - 06/2002
38	Drug Therapy (Chemotherapy) 01/2022 - 11/2003
23	Immunotherapy 11/2022 - 07/2011
23	Radiotherapy 03/2021 - 10/2006
8	Aftercare (After-Treatment) 01/2020 - 06/2007
7	Neoadjuvant Therapy 11/2019 - 10/2006
6	Lasers (Laser) 01/2018 - 01/2002
4	Chemoradiotherapy 11/2019 - 09/2007